Schwaederle M, Zhao M, Lee JJ, et al.. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol 2016;2:1452–1459.

• Crossref
• PubMed
Schwaederle M, Zhao M, Lee JJ, . Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol 2016;2:1452–1459.10.1001/jamaoncol.2016.212927273579)| false
• Search Google Scholar
• Export Citation

Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging trends in modern phase 1 oncology trials. N Engl J Med 2018;378:2242–2243.

• Crossref
• PubMed
Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging trends in modern phase 1 oncology trials. N Engl J Med 2018;378:2242–2243.2987452610.1056/NEJMc1803837)| false
• Search Google Scholar
• Export Citation

Gandara DR, Li T, Lara PN Jr, et al.. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer 2012;13:321–325.

• Crossref
• PubMed
Gandara DR, Li T, Lara PN Jr, . Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer 2012;13:321–325.10.1016/j.cllc.2012.05.00422677432)| false
• Search Google Scholar
• Export Citation

Diabetes Patient Advocacy Coalition. How the FDA drug approval process works. Available at: https://diabetespac.org/fda-drug-approval-process/. Accessed December 1, 2019.

• PubMed
Diabetes Patient Advocacy Coalition. How the FDA drug approval process works. Available at: https://diabetespac.org/fda-drug-approval-process/. Accessed December 1, 2019.)| false
• Export Citation

Selaru P, Tang Y, Huang B, et al.. Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib. Clin Transl Sci 2016;9:63–73.

• Crossref
• PubMed
Selaru P, Tang Y, Huang B, . Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib. Clin Transl Sci 2016;9:63–73.2684134610.1111/cts.12388)| false
• Search Google Scholar
• Export Citation

Kang SP, Gergich K, Lubiniecki GM, et al.. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 2017;28:1388–1398.

• Crossref
• PubMed
Kang SP, Gergich K, Lubiniecki GM, . Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 2017;28:1388–1398.10.1093/annonc/mdx076)| false
• Search Google Scholar
• Export Citation

FDA approves Vitrakvi (larotrectinib), the first ever TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion. Available at: https://www.prnewswire.com/news-releases/fda-approves-vitrakvi-larotrectinib-the-first-ever-trk-inhibitor-for-patients-with-advanced-solid-tumors-harboring-an-ntrk-gene-fusion1-2-300755551.html. Accessed December 1, 2019.

• PubMed
FDA approves Vitrakvi (larotrectinib), the first ever TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion. Available at: https://www.prnewswire.com/news-releases/fda-approves-vitrakvi-larotrectinib-the-first-ever-trk-inhibitor-for-patients-with-advanced-solid-tumors-harboring-an-ntrk-gene-fusion1-2-300755551.html. Accessed December 1, 2019.)| false
• Export Citation

Gyawali B, D’Andrea E, Franklin JM, Kesselheim AS. Response rates and durations of response for biomarker-based cancer drugs in non-randomized versus randomized trials. J Natl Compr Canc Netw 2020;18:36–43.

• Crossref
• PubMed
Gyawali B, D’Andrea E, Franklin JM, Kesselheim AS. Response rates and durations of response for biomarker-based cancer drugs in non-randomized versus randomized trials. J Natl Compr Canc Netw 2020;18:36–43.10.6004/jnccn.2019.7345)| false
• Search Google Scholar
• Export Citation

US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: https://www.fda.gov/drugs/scienceresearch/ucm572698.htm. Accessed December 9, 2019.

• PubMed
US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: https://www.fda.gov/drugs/scienceresearch/ucm572698.htm. Accessed December 9, 2019.)| false
• Export Citation

Osgood C, Mulkey F, Mishra-Kalyani PS, et al.. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 9508.

• Crossref
• PubMed
Osgood C, Mulkey F, Mishra-Kalyani PS, . FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 9508.10.1200/JCO.2019.37.15_suppl.9508)| false
• Search Google Scholar
• Export Citation